1
Versteegh, Matthijs M., Vermeulen, Karin M., Evers, Silvia M. A. A., de Wit, G. Ardine, Prenger, Rilana, Stolk, Elly A.
Veröffentlicht in: Versteegh , M M , Vermeulen , K M , Evers , S M A A , de Wit , G A , Prenger , R & Stolk , E A 2016 , ' Dutch Tariff for the Five-Level Version of EQ-5D ' , Value in Health , vol. 19 , no. 4 , pp. 343-352 . https://doi.org/10.1016/j.jval.2016.01.003;
2016
Veröffentlicht in: Versteegh , M M , Vermeulen , K M , Evers , S M A A , de Wit , G A , Prenger , R & Stolk , E A 2016 , ' Dutch Tariff for the Five-Level Version of EQ-5D ' , Value in Health , vol. 19 , no. 4 , pp. 343-352 . https://doi.org/10.1016/j.jval.2016.01.003;
2016
2
Ramos, Isaac Corro, Versteegh, Matthijs M., de Boer, Rudolf A., Koenders, Jolanda M. A., Linssen, Gerard C. M., Meeder, Joan G., Rutten-van Molken, Maureen P. M. H.
Veröffentlicht in: Ramos , I C , Versteegh , M M , de Boer , R A , Koenders , J M A , Linssen , G C M , Meeder , J G & Rutten-van Molken , M P M H 2017 , ' Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands : A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines ' , Value in Health , vol. 20 , no. 10 , pp. 1260-1269 . https://doi.org/10.1016/j.jval.2017.05.013;
2017
Veröffentlicht in: Ramos , I C , Versteegh , M M , de Boer , R A , Koenders , J M A , Linssen , G C M , Meeder , J G & Rutten-van Molken , M P M H 2017 , ' Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands : A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines ' , Value in Health , vol. 20 , no. 10 , pp. 1260-1269 . https://doi.org/10.1016/j.jval.2017.05.013;
2017
3